This website has been developed by Besins Healthcare (UK) Ltd.
This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.
Please confirm that:
Before first use, patients need to prepare the gel pump to ensure delivery of a consistent dose.
Remove the cap from the canister to reveal the plunger
Press the plunger down three times, collecting the gel on a tissue
Do not use the gel released and safely discard it in a rubbish bin
The pump is now ready to use and these steps do not have to be performed again.
Assure patients that application is straight forward and that they are aware of the following steps:
Wash your hands
Wash application areas before any direct skin contact with someone else.
Testogel® is flammable until dry.
Testosterone can be transferred to others through direct skin-on-skin contact. In order to prevent this, equip your patients with the following information:
How to avoid transfer risk:1
If a patient thinks they have transferred testosterone:1
If a patient misses a dose or removes the gel by accident, they do not need to reapply or take a ‘double’ dose. The gel should be applied at the usual time the following day.
For more information for patients, download the Testogel® 16.2 mg/g gel package leaflet, which is also contained within their medication.
It is important to manage your patient’s expectations and advise them that some of their symptoms will take longer than others to improve. This will help to ensure patients continue with the treatment even if results are not immediately seen.
Many of the symptoms of testosterone deficiency (TD) will start to improve within 3 months. However, the maximum effect of treatment on most symptoms is seen at 6–12 months.2
Find more information on specific symptom relief timelines.
Assess response to therapy at 2–4 weeks, 3–6 months, 12 months, and then annually thereafter.3,4
Aim for a target testosterone level of 15–30 nmol/L to achieve optimal response.3
Monitor haematocrit before treatment, at 3–6 months, 12 months, and annually thereafter. Decrease dosage or switch preparation if haematocrit is >0.54; if haematocrit remains high, consider stopping treatment and reintroduce at a lower dose.3
Assess prostate health by prostate-specific antigen test (PSA) and digital rectal exam (DRE) before commencing testosterone therapy (TTh) followed by PSA at 3–6 months, 12 months, and then every 12 months following.3
Assess cardiovascular risk before TTh is initiated and monitor cardiovascular risk throughout therapy.3
In addition to the general TTh monitoring described above, the Testogel® 16.2 mg/g gel Summary of Product Characteristics (SPC) also recommends that the following be monitored regularly: haemoglobin, liver function tests, and lipid profile. Please refer to the SPC for further information.
The recommended starting dose for Testogel® 50 mg Sachet is one sachet, for Testogel® 16.2 mg/g gel it is two actuations of the pump.5
There are no comparative dosing studies that advise on how patients can be switched from one formulation of Testogel® to the other. The guidance in the individual products’ SPC should be followed when starting and titrating the dose of a particular Testogel® formulation.1,5
TES/2020/009. April 2021.
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: email@example.com
Find out everything you need to know about treatment with Testogel® 16.2 mg/g gel and see advice on how to talk to patients about their testosterone therapy.